Seth Lederman
Known title: Chief Executive OfficerCIK: 0001563420
Seth Lederman's purchase track record
How the stock did after each of Seth Lederman's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
6
of 8 since September 28, 2021
Stock higher 6 months later
0%
3 months: 29%
Median 6-month return
-45.6%
3 months: -14.0%
Beat the S&P 500
0%
median -57.4% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/27/2026 | TNXP | $28K | pending | pending | — |
| 6/9/2026 | TNXP | $59K | +14.8% | pending | — |
| 3/31/2026 | TNXP | $63K | -7.2% | -29.8% | +17.5% |
| 3/18/2026 | TNXP | $223K | -14.0% | -17.1% | +14.0% |
| 5/15/2025 | TNXP | $86K | +157.9% | -30.1% | +13.9% |
| 6/29/2022 | TNXP | $34K | -66.3% | -80.1% | -0.9% |
| 3/25/2022 | TNXP | $25K | -74.6% | -92.5% | -18.7% |
| 9/28/2021 | TNXP | $7K | -33.9% | -61.0% | +6.4% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| TNXP | ▲ Buy | Open Market | 2,000 | $28K | 8/27/2026 | View on chart |
| TNXP | ▲ Buy | Open Market | 5,000 | $59K | 6/9/2026 | View on chart |
| TNXP | ▲ Buy | Open Market | 5,000 | $63K | 3/31/2026 | View on chart |
| TNXP | ▲ Buy | Open Market | 15,000 | $223K | 3/18/2026 | View on chart |
| TNXP | ▲ Buy | Open Market | 4,000 | $86K | 5/15/2025 | View on chart |
| TNXP | ▼ Sell | Other | 5 | $18 | 2/5/2025 | View on chart |
| TNXP | ▼ Sell | Other | 0 | $1 | 2/5/2025 | View on chart |
| TNXP | ▼ Sell | Other | 1 | $0 | 2/5/2025 | View on chart |
| TNXP | ▲ Buy | Open Market | 20,000 | $34K | 6/29/2022 | View on chart |
| TNXP | ▲ Buy | Open Market | 100,000 | $25K | 3/25/2022 | View on chart |
| TNXP | ▲ Buy | Open Market | 12,000 | $7K | 9/28/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
TNXP Secures Second Medicare Agreement for TONMYA
Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.
TNXP Secures Second Medicare Agreement for TONMYA. Tonix Pharmaceuticals announced a second major managed Medicare payer agreement for its drug TONMYA. The deal expands the drug’s coverage and could increase patient access. The agreement follows the first Medicare agreement and supports the company’s growth strategy. The news may influence investor perception of the drug’s commercial potential.